Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Change in Inventory (2016 - 2025)

Historic Change in Inventory for Niagen Bioscience (NAGE) over the last 13 years, with Q3 2025 value amounting to $4.4 million.

  • Niagen Bioscience's Change in Inventory rose 55346.43% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.2 million, marking a year-over-year increase of 49649.04%. This contributed to the annual value of -$5.3 million for FY2024, which is 340855.26% down from last year.
  • Latest data reveals that Niagen Bioscience reported Change in Inventory of $4.4 million as of Q3 2025, which was up 55346.43% from $3.2 million recorded in Q2 2025.
  • Niagen Bioscience's 5-year Change in Inventory high stood at $4.4 million for Q3 2025, and its period low was -$2.8 million during Q1 2023.
  • In the last 5 years, Niagen Bioscience's Change in Inventory had a median value of $446000.0 in 2022 and averaged $374105.3.
  • Per our database at Business Quant, Niagen Bioscience's Change in Inventory surged by 65641.03% in 2023 and then plummeted by 161384.62% in 2024.
  • Over the past 5 years, Niagen Bioscience's Change in Inventory (Quarter) stood at $926000.0 in 2021, then plummeted by 203.56% to -$959000.0 in 2022, then soared by 298.23% to $1.9 million in 2023, then crashed by 171.12% to -$1.4 million in 2024, then skyrocketed by 424.33% to $4.4 million in 2025.
  • Its Change in Inventory stands at $4.4 million for Q3 2025, versus $3.2 million for Q2 2025 and $2.0 million for Q1 2025.